Intravitreal bevacizumab and panretinal photocoagulation for proliferative diabetic retinopathy associated with vitreous hemorrhage

Retina

Volumn 29, Issue 8, 2009, Pages 1134-1140

  Huang, Yu Hsun ^a,b   Yeh, Po Ting ^b   Chen, Muh Shy ^b,c   Yang, Chang Hao ^b,c   Yang, Chung May ^b,c  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Intravitreal bevacizumab; Panretinal photocoagulation; Proliferative diabetic retinopathy; Vitreous hemorrhage

Indexed keywords

BEVACIZUMAB;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; LASER COAGULATION; MALE; PROLIFERATE DIABETIC RETINOPATHY; VITRECTOMY; VITREOUS BODY; VITREOUS HEMORRHAGE;

ADOLESCENT; ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; DIABETIC RETINOPATHY; FEMALE; HUMANS; LIGHT COAGULATION; MALE; MIDDLE AGED; RETINA; TREATMENT OUTCOME; VITRECTOMY; VITREOUS HEMORRHAGE;

EID: 70349150585     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181b094b7     Document Type: Article

References (26)

1. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 2006;26:275-278.
2. Chen E, Park CH. Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina 2006;26: 699-700.
3. Mason JO III, Nixon PA, White MF. Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 2006;142:685-688.
4. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bev-acizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006;113:1695.e1-e15.
5. Kuppermann BD, Thomas EL, de Smet MD, Grillone LR; Vitrase for Vitreous Hemorrhage Study Groups. Safety results of two phase III trials of an intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage. Am J Ophthalmol 2005;140:585-597.
6. Jorge R, Costa RA, Calucci D, Cintra LP, Scott IU. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina 2006;26:1006-1013.
7. Goff MJ, Johnson RN, McDonald HR, Ai E, Jumper JM, Fu A. Intravitreal bevacizumab for previously treated choroidal neo-vascularization from age-related macular degeneration. Retina 2007;27:432-438.
8. Nussenblatt RB, Palestine AG, Chan CC, Roberge F. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology 1985;92:467-471.
9. Yang CM, Yeh PT, Yang CH, Chen MS. Bevacizumab pretreatment and long-acting gas infusion on vitreous clear-up after diabetic vitrectomy. Am J Ophthalmol 2008;146:211-217.
10. Diabetic Retinopathy Study Research Group: Preliminary report on effects of photocoagulation therapy. Am J Ophthalmol 1976;81:383-396.
11. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy: ETDRS report number 9. Ophthalmology 1991;98:766-785.
12. Shimura M, Yasuda K, Nakazawa T, Kano T, Ohta S, Tamai M. Quantifying alterations of macular thickness before and after panretinal photocoagulation in patients with severe diabetic retinopathy and good vision. Ophthalmology 2003;110: 2386-2394.
13. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevaci-zumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36:331-335.
14. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006; 113:363-372.
15. Haritoglou C, Kook D, Neubauer A, et al. Intravitreal bevaci-zumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006;26:999-1005.
16. Shih CW, Yang CM, Chen MS, Wang TJ. Intravitreal injection of bevacizumab and gas for diabetic premacular hemorrhage with active fibrovascular proliferation. Graefes Arch Clin Exp Ophthalmol 2008;246:1547-1551.
17. Avery RL. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 2006;26:352-354.
18. Isaacs TW, Barry C. Rapid resolution of severe disc new vessels in proliferative diabetic retinopathy following a single intravitreal injection of bevacizumab (Avastin). Clin Experiment Ophthalmol 2006;34:802-803.
19. Ishikawa K, Honda S, Tsukahara Y, Negi A. Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy. Eye 2009;23:108-111.
20. Cooper B, Shah GK, Grand MG, Bakal J, Sharma S. Visual outcomes and complications after multiple vitrectomies for diabetic vitreous hemorrhage. Retina 2004;24:19-22.
21. Benedett R, Olk RJ, Arribas NP, et al. Transconjunctival anterior retinal cryotherapy for proliferative diabetic retinopathy. Ophthalmology 1987;94:612-619.
22. Mosier MA, Del Piero E, Gheewala SM. Anterior retinal cryotherapy in diabetic vitreous hemorrhage. Am J Ophthalmol 1985;100:440-444.
23. Arevalo JF, Wu L, Sanchez JG, et al. Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-months follow-up. Eye 2009;23:117-123.
24. Hotta K, Hirakata A, Ohi Y, et al. Ultrasound biomicroscopy for examination of the sclerotomy site in eyes with proliferative diabetic retinopathy after vitrectomy. Retina 2000;20:52-58.
25. Bhende M, Agraharam SG, Gopal L, et al. Ultrasound biomicros-copy of sclerotomy sites after pars plana vitrectomy for diabetic vitreous hemorrhage. Ophthalmology 2000;107:1792-11736
26. Hershberger VS, Augsburger JJ, Hutchins RK, Raymond LA, Krug S. Fibrovascular ingrowth at sclerotomy sites in vitrec-tomized diabetic eyes with recurrent vitreous hemorrhage: ultrasound biomicroscopy findings. Ophthalmology 2004;111: 1215-1221.